Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply

Documenti analoghi

• Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
  di: Benedikt Silvester Hofer, et al.
  Pubblicazione: (2024)
• Editorial: Carvedilol Remains the First‐Line Treatment of Portal Hypertension After the CALIBRE Trial
  di: Thomas Reiberger, et al.
  Pubblicazione: (2025)
• Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
  di: Benedikt Silvester Hofer, et al.
  Pubblicazione: (2026)
• Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
  di: Lukas Burghart, et al.
  Pubblicazione: (2026)
• Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
  di: Nina Dominik, et al.
  Pubblicazione: (2024)